
Explore the most recent data on adult ADHD with the president of the American Professional Society for ADHD and Related Disorders.
Dr Mattingly is an associate clinical professor at Washington University School of Medicine, and is a physician and principal investigator in clinical trials for Midwest Research Group.
Explore the most recent data on adult ADHD with the president of the American Professional Society for ADHD and Related Disorders.
Check out these APSARD 2024 updates from Greg Mattingly, MD, president of the American Professional Society for ADHD and Related Disorders.
In an exclusive interview, APSARD President Elect Greg Mattingly, MD, tells Psychiatric Times readers what they can expect at this year's meeting.
Updates from Day 2 at the National Academy of Sciences Conference on adult ADHD.
Check out these updates for the National Academy of Sciences Conference on adult ADHD, including new research, thoughtful discussions, and more!
Clinicians wrap up their discussion on novel, rapid-acting agents for major depressive disorder (MDD) with key insights and takeaways for providers.
Clinicians expand their discussion with a second patient case, highlighting similarities and differences between cases, and particular treatment algorithms that may be helpful.
Experts continue their discussion of the first patient case, explaining how glutamate-modulating therapies could help improve his symptoms and outcomes.
Experts use a major depressive disorder (MDD) patient case to provide clinical insights on managing MDD, and how they would educate patients about their condition.
Clinicians wrap up their discussion of three new agents approved for the treatment of major depressive disorder (MDD).
Clinicians continue their discussion of three new agents approved for the treatment of major depressive disorder (MDD).
Clinicians begin their review of three new agents approved for the treatment of major depressive disorder (MDD).
Experts highlight the current and prospective therapies for patients with MDD, highlighting key similarities and differences in patient pathophysiology, drug onset of action, and overall therapeutic limitations.
Experts discuss the impact of targeting glutamate receptors, highlighting its positive effects for patients with anhedonia.
Experts discuss the need to review current clinical guidelines in light of the need for rapid-acting treatment, especially as first-line treatments for some patients.
Clinicians discuss the particular benefits of rapid-acting agents for major depressive disorder (MDD), highlighting the gap glutamate-modulating agents fill in targeted therapies.
Experts continue their discussion on the role of glutamate receptors, explaining their role in stimulating neuroplasticity and neurogenesis.
Clinicians discuss the effects of glutamate modulation on neuroplasticity, memory, and cognitive function, highlighting their role in improving overall wellness for their patients.
Experts highlight the role of NMDA and AMPA receptors in major depressive disorder (MDD) and how new therapies are targeting novel mechanisms of action.
Clinicians discuss past treatment options compared to novel glutamate-modulating agents, highlighting their rapid onset of symptom relief.
Experts discuss the significance of glutamate in major depressive disorder, highlighting its links to neuroplasticity and stress.
Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, provide their practice pearls for community psychiatrists and psychiatric nurse practitioners who care for patients with major depressive disorder (MDD) to optimize their treatment and management.
Experts provide an overview of novel treatments, including glutamatergic, GABAergic, and psychedelic drugs, that are either approved or currently being evaluated in clinical studies for MDD (major depressive disorders).
Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, discuss the typical strategies for switching therapies for major depressive disorder (MDD).
Practitioners discuss the need to treat patients with major depressive disorder (MDD) to a complete remission vs a decline in symptomology.
Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, discuss best practices for monitoring and follow-up with patients with major depressive disorder (MDD) to ensure treatment efficacy and safety.
Practitioners discuss their approach to treatment with their patients with major depressive disorder (MDD).
Experts discuss how practitioners are viewing major depressive disorder (MDD) as a chronic condition vs an episodic condition.
Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, discuss navigating the challenge of a “one size fits all approach” when treating and identifying the specific needs of patients with major depressive disorder (MDD).
Practitioners discuss the rates of undertreatment in patients suffering from major depressive disorder (MDD).
Published: July 26th 2023 | Updated:
Published: July 12th 2023 | Updated:
Published: July 6th 2023 | Updated:
Published: July 12th 2023 | Updated:
Published: June 28th 2023 | Updated:
Published: July 26th 2023 | Updated: